JP7060906B2 - 抗ｉｌ－５抗体 - Google Patents

抗ｉｌ－５抗体 Download PDF

Info

Publication number
JP7060906B2
JP7060906B2 JP2019534656A JP2019534656A JP7060906B2 JP 7060906 B2 JP7060906 B2 JP 7060906B2 JP 2019534656 A JP2019534656 A JP 2019534656A JP 2019534656 A JP2019534656 A JP 2019534656A JP 7060906 B2 JP7060906 B2 JP 7060906B2
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
light chain
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019534656A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020513761A (ja
JP2020513761A5 (cg-RX-API-DMAC7.html
Inventor
マーク・テレンス・リッダメント
アンソニー・ドイル
アダム・クラーク
デイヴィッド・ホセ・サイモン・レイン
ブリジット・アン・コックジー
Original Assignee
セファロン インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セファロン インコーポレイテッド filed Critical セファロン インコーポレイテッド
Publication of JP2020513761A publication Critical patent/JP2020513761A/ja
Publication of JP2020513761A5 publication Critical patent/JP2020513761A5/ja
Application granted granted Critical
Publication of JP7060906B2 publication Critical patent/JP7060906B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2019534656A 2016-12-23 2017-12-20 抗ｉｌ－５抗体 Active JP7060906B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662438502P 2016-12-23 2016-12-23
US62/438,502 2016-12-23
PCT/US2017/067475 WO2018119016A1 (en) 2016-12-23 2017-12-20 Anti-il-5 antibodies

Publications (3)

Publication Number Publication Date
JP2020513761A JP2020513761A (ja) 2020-05-21
JP2020513761A5 JP2020513761A5 (cg-RX-API-DMAC7.html) 2021-01-14
JP7060906B2 true JP7060906B2 (ja) 2022-04-27

Family

ID=60972458

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019534656A Active JP7060906B2 (ja) 2016-12-23 2017-12-20 抗ｉｌ－５抗体

Country Status (20)

Country Link
US (2) US11111292B2 (cg-RX-API-DMAC7.html)
EP (1) EP3559030B1 (cg-RX-API-DMAC7.html)
JP (1) JP7060906B2 (cg-RX-API-DMAC7.html)
KR (1) KR102651290B1 (cg-RX-API-DMAC7.html)
CN (1) CN110267986B (cg-RX-API-DMAC7.html)
AR (1) AR110564A1 (cg-RX-API-DMAC7.html)
AU (1) AU2017379853B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019012929A2 (cg-RX-API-DMAC7.html)
CA (1) CA3048186A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019001730A1 (cg-RX-API-DMAC7.html)
EA (1) EA201991552A1 (cg-RX-API-DMAC7.html)
ES (1) ES2984636T3 (cg-RX-API-DMAC7.html)
IL (1) IL267271B2 (cg-RX-API-DMAC7.html)
MX (1) MX2019007642A (cg-RX-API-DMAC7.html)
NZ (1) NZ754606A (cg-RX-API-DMAC7.html)
PE (1) PE20191662A1 (cg-RX-API-DMAC7.html)
PH (1) PH12019501452A1 (cg-RX-API-DMAC7.html)
RU (1) RU2758008C2 (cg-RX-API-DMAC7.html)
WO (1) WO2018119016A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201904097B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201991552A1 (ru) * 2016-12-23 2020-01-09 Сефалон, Инк. Анти-il-5 антитела
SMT202600240T1 (it) 2017-05-26 2026-07-16 Glaxosmithkline Ip Dev Ltd Composizioni biofarmaceutiche e metodi correlati
CN113366016B (zh) * 2018-12-12 2022-12-16 上海开拓者生物医药有限公司 抗人白细胞介素5(il-5)单克隆抗体及其应用
JP7641908B2 (ja) 2019-03-29 2025-03-07 ジエンス ヘンルイ メデイシンカンパニー リミテッド Ｉｌ－５に対する抗体を含有する医薬組成物及びその使用
CN112745389B (zh) * 2019-10-29 2022-11-25 瑞阳(苏州)生物科技有限公司 结合人il-5的单克隆抗体及其应用
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US6056957A (en) * 1994-08-04 2000-05-02 Schering Corporation Humanized monoclonal antibodies against human interleukin-5
US5683892A (en) * 1994-12-23 1997-11-04 Smithkline Beecham Corporation DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
JP2001523083A (ja) * 1994-12-23 2001-11-20 スミスクライン・ビーチャム・コーポレイション Ｉｌ−５により媒介される疾病の治療に有用な組み換えｉｌ−５アンタゴニスト
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
ES2327830T3 (es) * 2002-03-29 2009-11-04 Schering Corporation Anticuerpos monoclonales humanos anti-interleuquina-5 y metodos y composiciones que los contienen.
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
ES3053874T3 (en) 2015-08-24 2026-01-27 Glaxosmithkline Ip No 2 Ltd Biopharmaceutical compositions
EP3365369A1 (en) * 2015-10-23 2018-08-29 Pfizer Inc Anti-il-2 antibodies and compositions and uses thereof
EA201991552A1 (ru) * 2016-12-23 2020-01-09 Сефалон, Инк. Анти-il-5 антитела

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
International Immunology，1999年，vol.11, no.12，p.1935-1943

Also Published As

Publication number Publication date
US20210355205A1 (en) 2021-11-18
EP3559030A1 (en) 2019-10-30
MX2019007642A (es) 2019-09-09
ZA201904097B (en) 2023-12-20
WO2018119016A1 (en) 2018-06-28
PE20191662A1 (es) 2019-11-11
EP3559030B1 (en) 2024-04-03
IL267271B2 (en) 2025-10-01
JP2020513761A (ja) 2020-05-21
AR110564A1 (es) 2019-04-10
CN110267986B (zh) 2023-05-09
AU2017379853A1 (en) 2019-07-04
ES2984636T3 (es) 2024-10-30
IL267271A (en) 2019-08-29
US20180186873A1 (en) 2018-07-05
RU2019123112A3 (cg-RX-API-DMAC7.html) 2021-04-05
RU2019123112A (ru) 2021-01-26
US12577298B2 (en) 2026-03-17
NZ754606A (en) 2023-06-30
EP3559030C0 (en) 2024-04-03
US11111292B2 (en) 2021-09-07
KR102651290B1 (ko) 2024-03-25
PH12019501452A1 (en) 2020-06-15
EA201991552A1 (ru) 2020-01-09
AU2017379853B2 (en) 2025-02-06
CN110267986A (zh) 2019-09-20
KR20190126769A (ko) 2019-11-12
BR112019012929A2 (pt) 2019-12-10
CA3048186A1 (en) 2018-06-28
IL267271B1 (en) 2025-06-01
CL2019001730A1 (es) 2019-09-27
RU2758008C2 (ru) 2021-10-25

Similar Documents

Publication Publication Date Title
JP7393337B2 (ja) 抗ｂ７－ｈ４抗体、その抗原結合断片及びその医薬用途
CN111712518B (zh) 对免疫球蛋白样转录物3(ilt3)具有特异性的抗体及其用途
US12577298B2 (en) Anti-IL-5 antibodies
US11525005B2 (en) Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof
CN110156892A (zh) 抗pd-l1抗体及其作为治疗剂及诊断剂的用途
AU2015384281B2 (en) Novel antibody binding to TFPI and composition comprising the same
MX2013014711A (es) Anticuerpos contra el g-csfr y sus usos.
EP4225437A1 (en) Cd1a antibodies and uses thereof
JP2025083342A (ja) ＴＧＦ－βＲＩＩ結合タンパク質
US20250059285A1 (en) Galectin-10 antibodies
HK40015055A (en) Anti-il-5 antibodies
HK40015055B (en) Anti-il-5 antibodies
EA042576B1 (ru) Анти-il-5 антитела
RU2779128C2 (ru) Антитело к cd40, его антигенсвязывающий фрагмент и его медицинское применение

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220202

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220314

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220412

R150 Certificate of patent or registration of utility model

Ref document number: 7060906

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250